Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
About this item
Full title
Author / Creator
Teh, T-C , Nguyen, N-Y , Moujalled, D M , Segal, D , Pomilio, G , Rijal, S , Jabbour, A , Cummins, K , Lackovic, K , Blombery, P , Thompson, E , Ekert, P G , Lessene, G , Glaser, S P , Huang, D C S , Roberts, A W , Guthridge, M A and Wei, A H
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Targeted therapies are frequently combined with standard cytotoxic drugs to enhance clinical response. Targeting the B-cell lymphoma 2 (BCL-2) family of proteins is an attractive option to combat chemoresistance in leukemia. Preclinical and clinical studies indicate modest single-agent activity with selective BCL-2 inhibitors (for example, venetocl...
Alternative Titles
Full title
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1924600708
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1924600708
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/leu.2017.243
